On March 12, 2024 City of Hope, one of the largest cancer research and treatment organizations in the United States, reported that it will present new findings at the AACR (Free AACR Whitepaper) Annual Meeting, which will take place April 5 to 10 in San Diego (Press release, City of Hope, MAR 12, 2024, View Source [SID1234641084]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the Phase 1 COBALT-RCC study"

Post this
This year, City of Hope doctors and scientists will also present data during AACR (Free AACR Whitepaper)’s Press Program and a clinical trials plenary session:

Monday, April 8, 2024, at 8:30 a.m.
Research by Ajay Goel, Ph.D., M.S., City of Hope professor and chair, Department of Molecular Diagnostics and Experimental Therapeutics, and Caiming Xu, Ph.D., a postdoctoral fellow in Goel’s lab, will be presented at an AACR (Free AACR Whitepaper) press conference. The abstract is titled "An exosome-based liquid biopsy for non-invasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter and prospective study."
Sunday, April 7, 2024, at 1 to 3 p.m.
Sumanta Kumar Pal, M.D., City of Hope chair, kidney and bladder cancer disease team, will present on "CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the Phase 1 COBALT-RCC study" during a clinical trials plenary session called, Beyond Immune Checkpoint Inhibition: Novel Immunotherapy Strategies.
Additional data presentations include:

"Multi-omics characterization of molecular features and global-local genomic ancestry analysis of colorectal cancer in Hispanic-Latinos"
Minisymposium session 3932: Monday, April 8, 2024, 3:35 to 3:50 p.m.
To investigate why Hispanic/Latino colorectal cancer (CRC) patients in Los Angeles face mortality rates up to 20% higher than their Caucasian counterparts, City of Hope’s Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S., City of Hope assistant professor, Department of Integrative Translational Sciences, and John D. Carpten, Ph.D., City of Hope’s chief scientific officer, Irell & Manella Cancer Center Director’s Distinguished Chair and Morgan & Helen Chu Director’s Chair of the Beckman Research Institute, along with a team of researchers, searched for mutations in CRC tumors by utilizing molecular profiling technologies. Results yielded important insights into the molecular characterization of CRC tumors and the multifaceted clinical and genomic heterogeneity within Hispanic/Latino populations, as well as crucial information on CRC tumor heterogeneity and the tumor microenvironment.

"Microbiome modification impacts PSCA directed chimeric antigen receptor (CAR) T cell therapy for prostate cancer"
Poster presentation 6676/7: Wednesday, April 10, 2024, 9 a.m. to 12:30 p.m.
John Murad, Ph.D., a staff scientist in the laboratory of Saul J. Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and colleagues developed methods to evaluate the impact of microbiome manipulation in the team’s established syngeneic PSCA+ prostate cancer mouse model. They found that the model was sensitive to microbiome modulation and that the use of patient-derived human fecal matter transfers can significantly impact PSCA-CAR T cell directed anti-tumor responses.
Late-Breaking Presentation

Wednesday, April 10, 2024, from 9 a.m. to 12:30 p.m.
Stephen Gruber, M.D., Ph.D., M.P.H., vice president, City of Hope National Medical Center, Evan and Ming Hsieh Family Director’s Chair of the Center for Precision Medicine and medical oncologist, will report on findings from an international team of researchers’ work investigating "Artificial intelligence measures of tumor infiltrating lymphocytes predict colorectal cancer-specific and overall survival." His presentation is titled "Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 3."
Symposiums and Educational Sessions

Marcel van den Brink, M.D., Ph.D., president of City of Hope Los Angeles and City of Hope National Medical Center, and Deana and Steve Campbell Chief Physician Executive Distinguished Chair, will lead a major symposium as chair of The Microbiome and Treatment Response to Cancer Therapy, to be held on Tuesday, April 9, 2024, from 10:15 a.m. to 11:45 a.m. He will also present on "The role of the intestinal microbiome in cancer immunotherapy," discussing clinical and preclinical studies that demonstrate how changes in the gut microbiome can affect outcomes after hematopoietic cell transplantation and CAR T cell therapy.
John D. Carpten, Ph.D., will chair and serve as a featured speaker for the presentation "Molecular Profiling in Breast Cancer and Racial/Ethnic Minorities: Dedicated to the Memory of Edith P. Mitchell."
Michael Caligiuri, M.D., City of Hope professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, is the chair for an educational session on Saturday, April 6, 2024, from 12:30 to 2 p.m. titled, The Road to Entrepreneurship. Industry experts will discuss how to get started, review criteria and find investors.
Michael Caligiuri, M.D., will also chair the inaugural AACR (Free AACR Whitepaper) event called From Cancer Discoveries to Patients on April 4 and 5. The event brings together leaders in clinical research, biotech and the investment community as part of AACR (Free AACR Whitepaper)’s commitment to expediting the advancement of lifesaving cancer discoveries.

On March 12, 2024 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, reported the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China (Press release, InnoCare Pharma, MAR 12, 2024, View Source [SID1234641083]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This multicenter, randomized-controlled, open-label clinical study is designed to evaluate the efficacy and safety of ICP-248 combined with orelabrutinib versus immunochemotherapy in treatment-naive patients with CLL/SLL.

ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies. BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the development of various hematologic malignancies. ICP-248 has an anti-tumor effect by selectively inhibiting BCL2 and restoring the mechanism of programmed cell death. The preliminary result has demonstrated a good efficacy and safety profile.

Orelabrutinib has been approved for marketing in China and Singapore, and all three approved indications related to lymphoma have been included in the National Reimbursement Drug List (NRDL) in China. In the treatment of relapsed/refractor CLL/SLL patients with orelabrutinib, the overall response rate and complete response rate reached 93.8% and 30% respectively, demonstrating an outstanding efficacy and safety profile.

Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, "InnoCare has developed strong pipeline in hemato-oncology that covers a variety of important hemato-oncology targets, including BTK, BLC2, CD19, CD20xCD3, E-3 ligase, etc. ICP-248 and orelabrutinib are important global assets of our company in the field of hematology, with multiple clinical studies conducted in China and the United States. We will accelerate clinical development and look forward to providing CLL/SLL patients with more efficient and safe treatment options."

CLL/SLL, one of the most common types of leukemia, is an indolent malignancy of B lymphocytes. There are 191,000 newly diagnosed CLL cases and 61,000 deaths every year globally1. The incidence rate of CLL/SLL is on the rise in China.

On March 12, 2024 TAE Life Sciences, a leading innovator in cancer treatment technologies, reported that the United States Patent and Trademark Office (USPTO) has granted the company’s U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe) for use in Boron Neutron Capture Therapy (BNCT) (Press release, TAE Life Sciences, MAR 12, 2024, View Source [SID1234641081]). This new patent underscores TAE Life Sciences’ commitment to advancing biologically targeted radiation therapy and marks a significant milestone in the field of radiation therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Boron Neutron Capture Therapy (BNCT) is a promising approach for the treatment of cancer and other diseases, utilizing boron-containing compounds to selectively deliver radiation to tumor cells while sparing healthy tissue. TAE Life Sciences’ patented borylated amino acid compounds, BTS and BTS(OMe), may offer an effective means of enhancing efficacy of BNCT, potentially opening new avenues for targeted treatments for cancer and immunological disorders.

"This patent represents a significant milestone for TAE Life Sciences, validating the innovative work of our research and development teams. We are excited about the potential impact of BTS and BTS(OMe) in advancing BNCT cancer treatment and improving patient outcomes." Rob Hill, CEO at TAE Life Sciences.

The patent covers not only the compositions of BTS and BTS(OMe) but also novel methods of their production, enabling scalable manufacturing processes to meet the growing demand for BNCT agents. With this patent, TAE Life Sciences solidifies its position as a leader in radiation therapy innovation, poised to transform the landscape of cancer treatment.

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit www.taelifesciences.com.

On March 12, 2024 Expert Systems, a leader in AI-enabled drug discovery, reported the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction (Press release, Eilean Therapeutics, MAR 12, 2024, View Source [SID1234641080]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Eilean’s lead PTPN2 inhibitor molecules demonstrate exceptional efficacy, selectivity, oral bioavailability and a good safety profile," commended Bill Farley, CBO at Expert Systems. "We’re proud to be Eilean’s partner & leverage our cutting-edge AI platform to help advance a new pipeline of best-in-class immuno-oncological therapy solutions with an improved safety and tolerability profile."

About Eilean Therapeutics’ PTPN2 Inhibitor Program

Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is ubiquitously expressed, primarily in hematopoietic and placental cells. As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.

On March 12, 2024 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, reported that it will present results of three preclinical studies as poster presentation at the AACR (Free AACR Whitepaper) Annual Meeting to be held in San Diego, USA, from April 5-10, 2024 (Press release, Mabwell Biotech, MAR 12, 2024, View Source [SID1234641079]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) Annual Meeting is one of the largest cancer research conferences in the world. The abstracts have been published on the AACR (Free AACR Whitepaper) official website.

Poster Presentation

01
Abstract title: Disrupting IL-11/IL-11R signaling by an efficacious anti-IL-11 antibody 9MW3811 enhances T cell tumor infiltration and synergizes with anti-PD-1 therapies in vivo
Abstract Number: 2365
Location: Poster Section 38
Poster Board Number: 11
Session Date and Time: Apr 8, 2024 9:00 AM – 12:30 PM PDT

02
Abstract title: 2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys
Abstract Number: 6349
Location: Poster Section 41
Poster Board Number: 10
Session Date and Time: Apr 9, 2024 1:30 PM – 5:00 PM PDT

03
Abstract title: 2MW4691, a novel CCR8/CTLA-4 bispecific antibody, displays potent anti-tumor efficacy by specifically depleting tumor-infiltrating Tregs and blocking CTLA-4 signaling on CD8+ T cells
Abstract Number: 6350
Location: Poster Section 41
Poster Board Number: 10
Session Date and Time: Apr 9, 2024 1:30 PM – 5:00 PM PDT

About 9MW3811

9MW3811 is a high-affinity humanized neutralizing antibody against IL-11. It is currently undergoing Phase 1 clinical trials in Australia and China. IL-11 is an important inflammation factor that plays a crucial role in fibrosis and the development and progression of tumors. Studies have shown that high expression of IL-11 is associated with the prognosis of various tumors such as lung cancer, liver cancer, and colorectal cancer. It has significant effects on various cells in the tumor microenvironment, including tumor cells, macrophages, T cells, and tumor-associated fibroblasts. 9MW3811 inhibits the activation of the downstream signaling pathway of IL-11 by blocking the binding of IL-11 to IL-11R, demonstrating good anti-tumor therapeutic effects in multiple preclinical pharmacodynamic models. When used in combination with anti-PD-1 antibodies, 9MW3811 significantly promotes the infiltration of CD8+ T lymphocytes, improving the T cell exhaustion caused by anti-PD-1 antibodies, thereby showing better combined anti-tumor efficacy.

About 2MW4991

2MW4991 is a high-specificity, high-affinity ADCC-enhanced antibody targeting integrin αvβ8. Integrin αvβ8 is an important activator of TGF-β, specifically regulating the activity of TGF-β in immune cells. Studies have found that integrin αvβ8 is highly expressed in certain tumors, and blocking αvβ8 can completely inhibit the release of TGF-β. 2MW4991 exhibits strong anti-tumor activity in immune-excluded tumor models, significantly promoting immune cell infiltration in immune-excluded tumors and greatly increasing the sensitivity of immune-excluded tumors to PD1 inhibitors.

About 2MW4691

2MW4691 is an ADCC-enhanced bispecific antibody targeting CCR8/CTLA-4. CTLA-4 is expressed on both CD8+ T cells and Tregs, and targeting CTLA-4 has a strong anti-tumor effect, but its clinical application is limited due to strong side effects. CCR8 is a specific marker for tumor infiltrating Tregs, almost not expressed on other immune cells and peripheral Tregs. 2MW4691 retains high affinity for CCR8 and attenuated CTLA-4 targeting activity, specifically eliminating tumor-infiltrating Tregs and blocking the immunosuppression mediated by CTLA-4 signaling on peripheral CD8+ T cells. It demonstrates strong anti-tumor activity in preclinical transgenic animal models and shows good safety in primates.